Clinical trials: Stem Cell Transplant Patients
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Stem Cell Transplant Complications, Delirium
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
This research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (HSCT).
- Trial name
- PHDC (NCT03489551)
- Testing
- Haldol
- Volunteers
- 17 people
- Sponsor
- Michelle Weckmann
Graft vs Host Disease, Myelodysplastic Syndromes
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of…
- Conditions
- Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid
- Trial name
- NCT00025662
- Testing
- RFT5-SMPT-dgA, Isolex system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Herpes Simplex
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.
- Trial name
- NCT01602562
- Testing
- VACV tablets (Adults or pediatrics) or granules (pediatrics)
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Bone Metastases
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Primary objectives: To determine the time to progression in subjects with breast cancer metastatic to bone only treated with 153Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).
- Trial name
- NCT00429507
- Testing
- 153 Sm-EDTMP, Questionnaire, Stem Cell Transplant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.
- Trial name
- NCT01503515
- Testing
- Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis
- Where
- 49 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- Children's Oncology Group
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Immunosuppression, Stem Cell Transplant
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.
- Conditions
- Immunosuppression, Stem Cell Transplant, Bone Marrow Transplant
- Trial name
- NCT04041219
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT01823198
- Testing
- Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
HCMV
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
- Trial name
- NCT02268526
- Testing
- CSJ148
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Delirium
Prevention of Delirium After Bone Marrow Transplantation
The purpose of this study is to find out if using bright light sessions during bone marrow transplant can prevent people from developing confusion also known as delirium.
- Trial name
- NCT01700816
- Testing
- Bright light therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing.
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002558
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus.
- Trial name
- NCT00424489
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Hemoglobinopathies, Sickle Cell Disease
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
The purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies…
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Thalassemia
- Trial name
- NCT00153985
- Testing
- Busulfex, Fludarabine, Alemtuzumab
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute